Several other analysts have also recently commented on the stock. Analysts at BNP Paribas (EPA: BNP) upgraded shares of Shire PLC from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, May 11st. Separately, analysts at Nomura (NYSE: NMR) initiated coverage on shares of Shire PLC in a research note to investors on Wednesday, April 4th. They set a “buy” rating on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Shire PLC in a research note to investors on Wednesday, April 4th. They set a “market perform” rating on the stock.
Shire PLC opened at 88.59 on Friday. Shire PLC has a 52-week low of $85.99 and a 52-week high of $108.79. The company has a market cap of $16.428 billion and a price-to-earnings ratio of 19.03.
Shire PLC last posted its quarterly earnings results on Thursday, April 26th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.72. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. Analysts expect that Shire PLC will post $1.52 EPS next quarter.
Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.